Fluconazole for the treatment of candidiasis: 15 years experience (Q35917407)

11 August 2017

1 reference

title

Fluconazole for the treatment of candidiasis: 15 years experience (English)

1 reference

11 August 2017

1 reference

1 reference

2

Jack D Sobel

1 reference

11 August 2017

Raymond Cha

1

1 reference

11 August 2017

language of work or name

1 reference

1 June 2004

1 reference

Expert Review of Anti-infective Therapy

11 August 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

11 August 2017

volume

2

1 reference

11 August 2017

issue

3

1 reference

11 August 2017

page(s)

357-366

1 reference

Invasive mycoses in organ transplant recipients: controversies in prophylaxis and management

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Increase inCandida kruseiInfection among Patients with Bone Marrow Transplantation and Neutropenia Treated Prophylactically with Fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Clinical management of oral and perioral candidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Fungal infections in patients with acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Oropharyngeal candidiasis: a review of its clinical spectrum and current therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Azole antifungal agents: emphasis on new triazoles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Oral azole drugs as systemic antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

The new generation of antifungal drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Increased gastric pH and the bioavailability of fluconazole and ketoconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Sputum levels of fluconazole in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Antifungal susceptibility testing: practical aspects and current challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Proficiency testing program for clinical laboratories performing antifungal susceptibility testing of pathogenic yeast species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Multicenter comparative evaluation of six commercial systems and the national committee for clinical laboratory standards m27-a broth microdilution method for fluconazole susceptibility testing of Candida species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

In vitro susceptibility of 245 yeast isolates to amphotericin B, 5-fluorocytosine, ketoconazole, fluconazole and itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Action of fluconazole (UK-49,858) in relation to other systemic antifungal azoles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Comparison of the efficacy of cilofungin, fluconazole and amphotericin B in the treatment of systemic Candida albicans infection in the neutropenic mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Treatment of vaginal Candida infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Current evaluation and management of vulvovaginitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Management of patients with recurrent vulvovaginal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Options for the management of mucosal candidiasis in patients with AIDS and HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Invasive oesophageal candidiasis: current and developing treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Fungal infections in neutropenia: current problems and chemotherapeutic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.357

21 January 2018

Identifiers

DOI

10.1586/14787210.2.3.357

1 reference

11 August 2017

1 reference